Title:
T CELL RECEPTOR-BASED BISPECIFIC POLYPEPTIDE MOLECULE AND USE THEREOF
Document Type and Number:
WIPO Patent Application WO/2023/246911
Kind Code:
A1
Abstract:
The present invention relates to a T cell receptor-based bispecific polypeptide molecule and use thereof. The present invention further provides a nucleic acid encoding the polypeptide molecule of the present invention, a vector or a vector system comprising the nucleic acid of the present invention, a host cell comprising the polypeptide molecule of the present invention, a conjugate and a pharmaceutical composition comprising the polypeptide molecule of the present invention, and a method for preventing or treating a disease in a subject using the polypeptide molecule of the present invention.
Inventors:
JIANG DONG (CN)
XIE XINGWANG (CN)
LI YONGHONG (CN)
WANG JIANGHUA (CN)
WANG XUEYAN (CN)
YAN BAOQI (CN)
BI JINGLEI (CN)
DANG ZIYI (CN)
XIE XINGWANG (CN)
LI YONGHONG (CN)
WANG JIANGHUA (CN)
WANG XUEYAN (CN)
YAN BAOQI (CN)
BI JINGLEI (CN)
DANG ZIYI (CN)
Application Number:
PCT/CN2023/101881
Publication Date:
December 28, 2023
Filing Date:
June 21, 2023
Export Citation:
Assignee:
CORREGENE BIOTECHNOLOGY CO LTD (CN)
International Classes:
C07K16/28; A61K39/395; A61P35/00; C07K16/30; C07K16/32; C07K16/46; C12N5/10; C12N15/85
Domestic Patent References:
| WO2019057124A1 | 2019-03-28 | |||
| WO2020057610A1 | 2020-03-26 |
Foreign References:
| CN114206932A | 2022-03-18 | |||
| CN111484555A | 2020-08-04 | |||
| CN108026179A | 2018-05-11 |
Other References:
MARK R. MIDDLETON ET AL.: "Tebentafusp, A TCR/Anti-CD3 Bispecific Fusion Protein Targeting gp100, Potently Activated Antitumor Immune Responses in Patients with Metastatic Melanoma", CLIN CANCER RES., vol. 26, no. 22, 15 November 2020 (2020-11-15), XP055826970, DOI: 10.1158/1078-0432.CCR-20-1247
Attorney, Agent or Firm:
LIU, SHEN & ASSOCIATES (CN)
Download PDF: